Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 06 Jan 2025 12:00 CET |
ULTIMOVACS | Ultimovacs ASA - Disclosure of voting rights of Extraordinary General Meeting | 20103010 Biotechnology | Total number of voting rights and capital |
| 05 Jan 2025 20:27 CET |
ULTIMOVACS | Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Dec 2024 09:37 CET |
ULTIMOVACS | Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Dec 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Dec 2024 08:00 CET |
ULTIMOVACS | ULTI - EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY | 20103010 Biotechnology | Ex Date |
| 17 Dec 2024 19:39 CET |
ULTIMOVACS | Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Dec 2024 19:24 CET |
ULTIMOVACS | Ultimovacs ASA - Mandatory notification of trade | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 17 Dec 2024 17:53 CET |
ULTIMOVACS | ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Nov 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 Oct 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Oct 2024 17:00 CEST |
ULTIMOVACS | Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv | 20103010 Biotechnology | Non-regulatory press releases |
| 11 Sep 2024 17:00 CEST |
ULTIMOVACS | Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Sep 2024 00:10 CEST |
ULTIMOVACS | Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Aug 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 15 Aug 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Aug 2024 13:59 CEST |
ULTIMOVACS | Ultimovacs Announces Notice of Resignation from Deputy Board Member | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Aug 2024 19:12 CEST |
ULTIMOVACS | Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Aug 2024 17:20 CEST |
ULTIMOVACS | Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 | 20103010 Biotechnology | Non-regulatory press releases |
| 24 Jun 2024 21:00 CEST |
ULTIMOVACS | Ultimovacs ASA announces revised terms of the employee share option program | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Jun 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Jun 2024 14:15 CEST |
ULTIMOVACS | Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 07 May 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Apr 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 24 Apr 2024 16:14 CEST |
ULTIMOVACS | Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Apr 2024 14:42 CEST |
ULTIMOVACS | Ultimovacs ASA - Annual General Meeting held on April 18, 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Apr 2024 22:10 CEST |
ULTIMOVACS | Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Apr 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting | 20103010 Biotechnology | Total number of voting rights and capital |
| 09 Apr 2024 20:00 CEST |
ULTIMOVACS | Ultimovacs - Invitation to Business Update on April 17, 2024 | 20103010 Biotechnology | Non-regulatory press releases |
| 04 Apr 2024 07:00 CEST |
ULTIMOVACS | Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Mar 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Mar 2024 13:27 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Mar 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA: Annual Report 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
| 09 Mar 2024 11:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trades by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 23:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trades by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 08:13 CET |
ULTIMOVACS | Ultimovacs ASA – Mandatory trade notification and disclosure of holding | 20103010 Biotechnology | Major shareholding notifications |
| 07 Mar 2024 23:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Mar 2024 16:37 CET |
ULTIMOVACS | Ultimovacs ASA – Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 07 Mar 2024 11:26 CET |
ULTIMOVACS | Ultimovacs ASA – Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 07 Mar 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Mar 2024 18:41 CET |
ULTIMOVACS | Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Feb 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Feb 2024 07:00 CET |
ULTIMOVACS | Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Feb 2024 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Feb 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Jan 2024 07:00 CET |
ULTIMOVACS | Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 Jan 2024 18:57 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 02 Jan 2024 19:25 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 19 Dec 2023 16:51 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Dec 2023 08:39 CET |
ULTIMOVACS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Dec 2023 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |